Immune mediation of hypersensitivity adverse drug reactions: implications for therapy

Bibliography

• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic adverse drug reactions: past, present and future. Chem Res Toxicol 2008;21:89-92
   Google Scholar
• Naisbitt DJ, Pirmohamed M, Park BK. Immunopharmacology of hypersensitivity reactions to drugs. Curr Allergy Asthma Rep 2003;3:22-9
   PubMed Web of Science ®Google Scholar
• Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor, Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977. p. 10
   Google Scholar
• Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Safety 1994;11:196-212
   PubMed Web of Science ®Google Scholar
• Thien FC. Drug hypersensitivity. Med J Aust 2006;185(6):333-8
   PubMed Web of Science ®Google Scholar
• Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use. Report of the nomenclature review committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-6
   PubMed Web of Science ®Google Scholar
• Greenberger PA. 8. Drug allergy. J Allergy Clin Immunol 2006;117(2 Suppl Mini-Primer):S464-70
   PubMed Web of Science ®Google Scholar
• Kawabata TT, Haggerty HG, Lavin AL, Adkinson NF. Meeting Review: Immune-Mediated Drug Hypersensitivities Reactions (IDHR) Workshop: mechanisms to increase IDHR research opportunities. J Immunotoxicol 2004;1:201-5
   Google Scholar
• Rieder MJ. Hypersensitivity adverse drug reactions in children: pathophysiology and therapeutic implications. Curr Ther Res 2001;62(12):913-29
   Web of Science ®Google Scholar
• Pirmohammed M. Anticipating, investigating and managing the adverse effects of drugs. Clin Med 2005;5(1):23-6
   PubMed Web of Science ®Google Scholar
• Zaccara G, Franciotta D, Perucca E. Critical review: idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48(7):1223-44
   PubMed Web of Science ®Google Scholar
• Coombs PR, Gell PG. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR, editor, Clinical aspects of immunology. Oxford University Press, Oxford. 1968. p. 575-96
   Google Scholar
• Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-93
   PubMed Web of Science ®Google Scholar
• Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions. Curr Pharm Des 2008;14(27):2778-91
   PubMed Web of Science ®Google Scholar
• Friedmann PS, Lee MS, Friedmann AC, Barnetson RS. Mechanisms in cutaneous drug hypersensitivity reactions. Clin Exp Allergy 2003;33:861-72
   PubMed Web of Science ®Google Scholar
• Gruchalla RS, Pirmohamed M. Clinical practice: antibiotic allergy. N Engl J Med 2006;354(6):601-9
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Menne T, Elberling J, et al. Hypersensitivity to local anaesthetics – update and proposal of evaluation algorithm. Contact Dermatitis 2008;59(2):69-78
   PubMed Web of Science ®Google Scholar
• Zhao Z, Baldo BA, Baumgart KW, Mallon DF. Fine structural recognition specificities of IgE antibodies distinguishing amoxicillanyl determinants in allergic subjects. J Mol Recognit 2001;14:300-7
   PubMed Web of Science ®Google Scholar
• Baldo BA, Zhao Z, Pham NM. Antibiotic allergy: immunochemical and clinical considerations. Curr Allergy Asthma Rep 2008;8(1):49-55
   PubMed Web of Science ®Google Scholar
• Buchmiller BL, Khan DA. Evaluation and management of pediatric drug allergy reactions. Curr Allergy Asthma Rep 2007;7(6):402-9
   PubMed Web of Science ®Google Scholar
• Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2008;8 (4):CD006312
   Google Scholar
• Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305(13):722-7
   PubMed Web of Science ®Google Scholar
• Shear NH, Spielberg SP. In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol 1985;63(11):1370-2
   PubMed Web of Science ®Google Scholar
• Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105(2):179-84
   PubMed Web of Science ®Google Scholar
• Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 1988;244(2):724-8
   PubMed Web of Science ®Google Scholar
• Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987;36:581-90
   PubMed Web of Science ®Google Scholar
• Speirs RS. Multiple cellular and subcellular responses to antigen. Literature review and hypothesis of immunization. Immunochemistry 1971;8(7):665-89
   PubMedGoogle Scholar
• Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935;61:643-56
   PubMedGoogle Scholar
• Beaune P, Dansette PM, Mansuy D, et al. Human antiendoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987;84:551-5
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metabol Rev 2006;38(4):745-53
   PubMed Web of Science ®Google Scholar
• Knowles SR, Shapiro LE, Shear NH. Reactive metabolites and adverse drug reactions: clinical considerations. Clin Rev Allergy Immunol 2003;24(3):229-38
   PubMed Web of Science ®Google Scholar
• Park BK, Naisbitt DJ, Gordon SF, et al. Metabolic activation in drug allergies. Toxicology 2001;158(1-2):11-23
   PubMed Web of Science ®Google Scholar
• Tschen AC, Rieder MJ, Oyewumi LK, Freeman DS. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 1999;65(5):526-32
   PubMed Web of Science ®Google Scholar
• Tabatabaei AR, Thies RL, Abbott FS. Assessing the mechanism of metabolism-dependent valproic acid-induced in vitro cytotoxicity. Chem Res Toxicol 1999;12(4):323-30
   PubMed Web of Science ®Google Scholar
• Kearns GL, Wheeler JG, Rieder MJ, Reid J. Serum-sickness like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. Clin Pharmacol Ther 1998;63(6):686-93
   PubMed Web of Science ®Google Scholar
• Uetrecht J, Zahid N, Tehim A, et al. Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 1997;104(1-2):117-9
   PubMed Web of Science ®Google Scholar
• Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions – new concepts. Clin Exp Allergy 2007;37:989-99
   PubMed Web of Science ®Google Scholar
• Pichler W, Beeler A, Keeller M, et al. Pharmacological interaction of drugs with immune receptors with immune receptors: the p-i concept. Allergol Int 2006;55(1):17-25
   PubMedGoogle Scholar
• Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity to carbamazepine: characterization of the specificity, phenotype and cytokine profile of drug-specific T cell lines. Mol Pharmacol 2003;63:732-41
   PubMed Web of Science ®Google Scholar
• Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigene hypersensitivity. J Allergy Clin Immunol 2003;111:1393-403
   PubMed Web of Science ®Google Scholar
• Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118:233-41
   PubMed Web of Science ®Google Scholar
• Schnyder B, Mauri-Hellwig D, Zanni M, et al. Direct MHC-dependent presentation of the drug sulfamethoxazole to human αβ T cell clones. J Clin Invest 1997;100:136-41
   PubMed Web of Science ®Google Scholar
• Schmidt DA, Depta JP, Pichler W. T cell mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 2006;36:59-69
   PubMed Web of Science ®Google Scholar
• Zanni MP, Mauri-Hellwig D, Brander C, et al. Characterization of lidocaine-specific T cells. J Immunol 1997;158:1139-48
   PubMed Web of Science ®Google Scholar
• Zanni MP, von Greyerz S, Harl Y, et al. Recognition of local anesthetics by αβ T cells. J Invest Dermatol 1999;112:197-204
   PubMed Web of Science ®Google Scholar
• Depta JP, Altznauer F, Gamerdinger K, et al. Drug interaction with T cell receptors determines degree of cross-reactivity. J Allergy Clin Immunol 2004;113:519-27
   PubMed Web of Science ®Google Scholar
• Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted processing – and metabolism-independent pathway of drug recognition by human αβ T lymphocytes. J Clin Invest 1998;102:1591-8
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994;12:91-1045
   Google Scholar
• Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the danger hypothesis and innate immune system. Chem Res Toxicol 1999;12(5):387-95
   PubMed Web of Science ®Google Scholar
• Naisbitt DJ, Gordon SF, Pirmohammed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propogation of immune responses elicited by drug treatment. Drug Saf 2000;23(6):483-507
   PubMed Web of Science ®Google Scholar
• O'Neill L. Toll-like receptors and the danger hypothesis. Trends Immunol 2001;8:421
   Google Scholar
• Sequin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003;3(4):235-42
   PubMedGoogle Scholar
• Liu L, Inoue H, Nakayama H, et al. The endogenous danger signal uric acid augments contact hypersensitivity responses in mice. Pathobiology 2007;74(3):177-85
   PubMed Web of Science ®Google Scholar
• Lu W, Li X, Uetrecht JP. Changes in gene expression induced by carbamazepine and phenytoin: testing the danger hypothesis. J Immunotoxicol 2008;5(2):107-13
   PubMed Web of Science ®Google Scholar
• Pacitto SR, Uetrecht JP, Boutros PC, Popovic M. Changes in gene expression induced by tienillic acid and sulfamethoxazole: testing the danger hypothesis. J Immunotoxicol 2008;4(4):253-66
   Web of Science ®Google Scholar
• Hertl M, Jugert F, Merk HF. CD8+ dermal T-cells from a sulfamethoxazole -induced bullous exanthema proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995;132:215-20
   PubMed Web of Science ®Google Scholar
• Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfamethoxazole, phenytoin and carbamazepine. J Immunol 1995;155:462-72
   PubMed Web of Science ®Google Scholar
• Hashizume H, Takigawa M, Tokura Y. Characterization of drug-specific T-cells in phenobarbital-induced eruption. J Immunol 2002;168:5359-68
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Hari Y, Frutig K, et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000;115:647-52
   PubMed Web of Science ®Google Scholar
• Wu Y, Farrell J, Pirmohamed M, et al. Generation and characterization of antigen specific CD4+, CD8+ and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-81
   PubMed Web of Science ®Google Scholar
• Sanderson DJ, Naisbitt DJ, Farrell J, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007;178(9):5533-42
   PubMed Web of Science ®Google Scholar
• Naisbitt DJ, Pirmohammed M, Park BK. Immunological principles of T cell mediated adverse drug reactions in skin. Exp Opin Drug Saf 2007;6(2):109-24
   PubMed Web of Science ®Google Scholar
• Lavergne SN, Park BK, Naisbitt DJ. The roles of drug metabolism in the pathogenesis of T cell mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol 2008;8(4):299-307
   PubMed Web of Science ®Google Scholar
• Evans R, 3rd KIM, K MAHR. Current concepts in allergy: drug reactions. Curr Probl Pediatr 1991;21(5):185-92
   PubMedGoogle Scholar
• Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8(1):5
   PubMedGoogle Scholar
• Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev 2002;(4):CD001435
   Google Scholar
• Krivoy N, Taer M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 2006;1(3):289-99
   PubMedGoogle Scholar
• Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007;27(10):1425-39
   PubMed Web of Science ®Google Scholar
• Sheridan RL, Weber JM, Schulz JT, et al. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999;20(6):497-500
   PubMedGoogle Scholar
• Ringheanu M, Laude TA. Toxic epidermal necrolysis in children–an update. Clin Pediatr (Phila) 2000;39(12):687-94
   PubMed Web of Science ®Google Scholar
• Spies M, Sanford AP, ili Low JF, et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatr 2001;108(5):1162-8
   PubMed Web of Science ®Google Scholar
• Sanclemente G, De la Roche CA, Escobar CE, Falabella R. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 1999;38(11):878-9
   PubMed Web of Science ®Google Scholar
• Inamo Y, Okubo T, Wada M, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 2002;127(1):89-94
   PubMed Web of Science ®Google Scholar
• Aihara Y, Ito R, Ito S, et al. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatr Int 2007;49(5):659-62
   PubMed Web of Science ®Google Scholar
• Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36(3):218-21
   PubMed Web of Science ®Google Scholar
• Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40(3):458-61
   PubMed Web of Science ®Google Scholar
• Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol 1998;139:1127-8
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Laterjet J, Roujeau JC, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9
   PubMed Web of Science ®Google Scholar
• Mitchell JH. Stevens Johnson syndrome: treatment with corticosteroids. Postgrad Med J 1958;34:384-8
   PubMedGoogle Scholar
• Kim PS, Goldfarb IW, Gaisford JC, Slater H. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiological review with recommendations for a treatment protocol. J Burn Care Rehabil 1983;4:91-100
   Google Scholar
• Halebian PH, Corder VJ, Madden MR, et al. Improved burn care survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12
   PubMed Web of Science ®Google Scholar
• Patterson R, Dykewicz MS, Gonzalzles A, et al. Erythema multiforme and Stevens Johnson syndrome: descriptive and therapeutic controversy. Chest 1990;98:331-6
   PubMed Web of Science ®Google Scholar
• Patterson R, Grammer LC, Greenberger PA, et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc 1992;13(2):89-95
   PubMedGoogle Scholar
• Pattterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994;74:27-34
   Google Scholar
• Englelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997;18:520-4
   PubMedGoogle Scholar
• Kakourou T, Klontza D, Soteropoulou F, Kattamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr 1997;156(2):90-3
   PubMed Web of Science ®Google Scholar
• Cheriyan S, Patterson R, Greenberger PA, et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 2000;21:101-5
   Google Scholar
• Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000;21(2):101-05
   PubMed Web of Science ®Google Scholar
• Schultz JT, Sheridan RL, Ryan CM, et al. A ten year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204
   PubMedGoogle Scholar
• Bahna SL, Khalili B. New concepts in the management of adverse drug reactions. Allergy Asthma Proc 2007;28(5):517-24
   PubMed Web of Science ®Google Scholar
• Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282(5388):490-3
   PubMed Web of Science ®Google Scholar
• Stur K, Karlhofer FM, Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 2007;127:802-7
   PubMed Web of Science ®Google Scholar
• Cazzola G, Nicolussi M, Carraro F. High-dose i.v. 7S immunoglobulin treatment in Stevens-Johnson syndrome. Helvetica Paediatrica Acta 1986;41:87-8
   PubMedGoogle Scholar
• Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000;27(10):2494-7
   PubMed Web of Science ®Google Scholar
• Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47(4):548-52
   PubMed Web of Science ®Google Scholar
• Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatr 2003;112:1430-6
   PubMed Web of Science ®Google Scholar
• Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatol 2003;207(1):96-9
   PubMed Web of Science ®Google Scholar
• Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32
   PubMed Web of Science ®Google Scholar
• Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003;91(1):86-91
   PubMed Web of Science ®Google Scholar
• Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Internat J Dermatol 2004;43(11):847-51
   PubMed Web of Science ®Google Scholar
• Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005;71(6):398-400
   PubMedGoogle Scholar
• Arca E, Kose O, Erbil AH, et al. A 2-year-old girl with Stevens–Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin. Pediatr Dermatol 2005;22(4):317-20
   PubMed Web of Science ®Google Scholar
• Kalyoncu M, Cimsit G, Cakir M, Okten A. Toxic epidermal necrolysis treated with intravenous immunoglobulin and granulocyte colony-stimulating factor. Indian Pediatr 2004;41(4):392-5
   PubMedGoogle Scholar
• Pasic S. Intravenous immunoglobulin in toxic epidermal necrolysis. Int J Dermatol 2006;45(9):1117-8
   PubMed Web of Science ®Google Scholar
• Zipitis CS, Thalange N. Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. Eur J Pediatr 2007;166(6):585-8
   PubMed Web of Science ®Google Scholar
• Mittmann N, Chan BC, Knowles S, Shear NH. IVIG for the treatment of toxic epidermal necrolysis. Skin Therapy Lett 2007;12(1):7-9
   PubMedGoogle Scholar
• Kelemen JJ, Cioffi WG, McManus WF, et al. Burn center care of patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-8
   PubMed Web of Science ®Google Scholar
• Lehrer-Bell KA, Kirsner RS, Tallman PG, Kerdel FA. Treatment of the cutaneous involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis with silver nitrate-impregnated dressings. Arch Dermatol 1998;134(7):877-9
   PubMed Web of Science ®Google Scholar
• Bannasch H, Kontny U, Kruger M, et al. A semisynthetic bilaminar skin substitute used to treat pediatric full-body toxic epidermal necrolysis: wraparound technique in a 17-month-old girl. Arch Dermatol 2004;140(2):160-2
   PubMed Web of Science ®Google Scholar
• Asz J, Asz D, Moushey R, et al. Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing. J Pediatr Surg 2006;41(12):e9-12
   PubMed Web of Science ®Google Scholar
• Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988;82(6):1826-32
   PubMed Web of Science ®Google Scholar
• Elzaballaai AA, Knowles SR, Rieder MJ, et al. Systematic review of different in vivo and in vitro tests used for the diagnosis of anticonvulsant hypersensitivity syndrome (AHS): I-Patch Test (PT). Drug Saf [In Press]
   Google Scholar
• Uetrecht JP. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS 2006;7(4):e914-21
   PubMed Web of Science ®Google Scholar
• Popovic M, Caswell JL, Mannargudi B, et al. Study of the sequence of events involved in nevaripine-induced skin rash in Brown Norway rats. Chem Res Toxicol 2006;19(9):1205-14
   PubMed Web of Science ®Google Scholar
• Chen J, Mannargudi BM, Xu L, Uetrecht J. Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 2008;21(9):1862-70
   PubMed Web of Science ®Google Scholar
• Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-7
   PubMed Web of Science ®Google Scholar
• Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22(15):2025-33
   PubMed Web of Science ®Google Scholar
• Ueta M, Sotozono C, Inatomi T, et al. Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 2008;92(7):989-91
   PubMed Web of Science ®Google Scholar
• Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008;22(4):540-1
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-79
   PubMed Web of Science ®Google Scholar
• Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18(2):99-107
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Arbuckle JB, Bowman CE, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007;8(12):1661-91
   PubMed Web of Science ®Google Scholar
• Mann MW, Pons G. Various pharmacogenetic aspects of antiepileptic drug therapy: a review. CNS Drugs 2007;21(2):143-64
   PubMed Web of Science ®Google Scholar
• Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J 2006;6(4):265-8
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102(11):4134-9
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428(6982):486
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Krauss RM, Roden DM, et al. When good drugs go bad. Nature 2007;446:975-7
   PubMed Web of Science ®Google Scholar